Skip to main content
SpringerLink
Log in

Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This 3-month multicenter, investigator-masked, parallel-group study compared brimonidine Purite and bimatoprost (brimP/bim) with timolol gel-forming solution and latanoprost (tim/latan) in 28 patients with open-angle glaucoma or ocular hypertension. IOP was measured at baseline and 2 hours after morning instillation at weeks 2, 4, and 12. The primary outcome measure was the mean IOP reduction from baseline. Secondary measures were the percentage of patients in each group who achieved specific low target pressures and the incidence of adverse events. Mean IOP at baseline was 24.8 mm Hg in each group. At follow-up visits, mean reductions from baseline ranged from 8.5 to 9.0 mm Hg with brimP/bim and from 7.5 to7.7 mm Hg with tim/latan. More patients achieved low target pressures with brimP/bim. At week 12, 69.2% of brimP/bim patients and 27.3% of tim/latan patients had IOPs of 16 mm Hg or lower (P = .024). Both regimens were well tolerated, and adverse events were infrequent. The combination of brimonidine Purite and bimatoprost was well tolerated and at least as effective as Timoptic-XE and latanoprost in reducing IOP. More patients achieved low target IOPs with brimonidine Purite and bimatoprost than with Timoptic-XE and latanoprost. A larger study is needed to confirm these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye.Arch Ophthalmol. 1978;96:2045–2048.

    PubMed  CAS  Google Scholar 

  2. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.Ophthalmology. 1993;100:1297–1304.

    PubMed  CAS  Google Scholar 

  3. Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol.Am J Ophthalmol. 2002;133:753–757.

    Article  PubMed  CAS  Google Scholar 

  4. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma.J Glaucoma. 1999;8:24–30.

    Article  PubMed  CAS  Google Scholar 

  5. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.J Ocul Pharmacol Ther. 2000;16:251–259.

    PubMed  CAS  Google Scholar 

  6. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.Am J Ophthalmol. 1999;128:692–696.

    Article  PubMed  CAS  Google Scholar 

  7. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review.Drugs. 2000;59:411–434.

    Article  PubMed  CAS  Google Scholar 

  8. Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use.Clin Ther. 2000;22:167–208.

    Article  PubMed  CAS  Google Scholar 

  9. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients.Br J Ophthalmol. 2000;84:710–713.

    Article  PubMed  CAS  Google Scholar 

  10. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am J Ophthalmol. 2001;132:472–484.

    Article  PubMed  CAS  Google Scholar 

  11. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.Surv Ophthalmol. 1997;41(suppl 2):S129-S138.

    PubMed  Google Scholar 

  12. Brubaker RF. Mechanism of action of bimatoprost (Lumigan).Surv Ophthalmol. 2001;45(suppl 4):S347-S351.

    Article  PubMed  Google Scholar 

  13. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.Am J Ophthalmol. 1999;128:8–14.

    Article  PubMed  CAS  Google Scholar 

  14. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.Surv Ophthalmol. 2001;45(suppl 4):S361-S368.

    Article  PubMed  Google Scholar 

  15. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.Surv Ophthalmol. 2001;45(suppl 4):S353-S360.

    Article  PubMed  Google Scholar 

  16. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.Adv Ther. 2001;18:110–121.

    PubMed  CAS  Google Scholar 

  17. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.Am J Ophthalmol. 2003;135:55–63.

    Article  PubMed  CAS  Google Scholar 

  18. Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.Drugs Aging. 2002;19:231–248.

    Article  PubMed  CAS  Google Scholar 

  19. David R. Brimonidine (Alphagan): a clinical profile four years after launch.Eur J Ophthalmol. 2001;11(suppl 2):S72-S77.

    PubMed  Google Scholar 

  20. Konstas AG, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.Am J Ophthalmol. 2001;131:729–733.

    Article  PubMed  CAS  Google Scholar 

  21. DuBiner HB, Mroz M, Shapiro AM, Dirks MS. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.Clin Ther. 2001;23:1969–1983.

    Article  PubMed  CAS  Google Scholar 

  22. Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial.J Ocul Pharmacol Ther. 2000;16:3–18.

    Article  PubMed  CAS  Google Scholar 

  23. O’Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost.Am J Ophthalmol. 2002;133:836–837.

    Article  PubMed  CAS  Google Scholar 

  24. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.Clin Ther. 2001;23:604–619.

    Article  PubMed  CAS  Google Scholar 

  25. Vidal-Sanz M, Lafuente MP, Mayor-Torroglosa S, et al. Brimonidine’s neuroprotective effects against transient ischaemia-induced retinal ganglion cell death.Eur J Ophthalmol. 2001;11(suppl 2):S36-S40.

    PubMed  Google Scholar 

  26. Lafuente MP, Villegas-Perez MP, Mayor S, Aguilera ME, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study.Exp Eye Res. 2002;74:181–189.

    Article  PubMed  CAS  Google Scholar 

  27. Ruiz Lapuente C, Ruiz Lapuente A, Link B. Influence of topical brimonidine on visual field in glaucoma.Eur J Ophthalmol. 2001;11(suppl 2):S67-S71.

    Google Scholar 

  28. Katz LJ. Twelve-month evaluation of brimonidine Purite versus brimonidine in patients with glaucoma or ocular hypertension.J Glaucoma. 2002;11:119–126.

    Article  PubMed  Google Scholar 

  29. Physicians’ Desk Reference® for Ophthalmic Medicines. Montvale, NJ: Medical Economics; 2002.

  30. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci. 2000;41:2566–2573.

    PubMed  CAS  Google Scholar 

  31. Zeimer RC. Circadian variations in intraocular pressure. In: Ritch R, Schields MB, Krupin T, eds.The Glaucomas. St. Louis, Mo: CV Mosby; 1996:429–445.

    Google Scholar 

  32. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients.Am J Ophthalmol. 1999;127:20–26.

    Article  PubMed  CAS  Google Scholar 

  33. Konstas AG, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Comparison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% in exfoliation and primary open-angle glaucoma.Acta Ophthalmol Scand. 1999;77:541–543.

    Article  PubMed  CAS  Google Scholar 

  34. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial.Arch Ophthalmol. 2002;120:915–922.

    PubMed  CAS  Google Scholar 

  35. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.Ophthalmology. 2002;109:307–314.

    Article  PubMed  Google Scholar 

  36. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.J Glaucoma. 2001;10:220–226.

    Article  PubMed  CAS  Google Scholar 

  37. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.Am J Ophthalmol. 2000;130:429–440.

    Article  Google Scholar 

  38. Kolker AE, May MM, Day SE. Frequency of contraindications to topical beta-blockers in a glaucoma population.Invest Ophthalmol Vis Sci. 1999;40:S514.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Tennessee Health Science Center, 956 Court Avenue, 38163, Memphis, Tennessee

    Peter A. Netland MD, PhD

  2. Ophthalmic Research Associates, Inc., North Andover, Massachusetts

    Michael Mroz & Sarah A. Rosner MPH

  3. West Coast Eye Care Associates, San Diego, California

    Barry Katzman MD

  4. Macy Eye Center, Los Angeles, California

    Jonathan I. Macy MD

Authors
  1. Peter A. Netland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Mroz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah A. Rosner MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barry Katzman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jonathan I. Macy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Netland, P.A., Mroz, M., Rosner, S.A. et al. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Therapy 20, 20–30 (2003). https://doi.org/10.1007/BF02850116

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850116

Keywords

Search

Navigation